Add To Cart

Section 3
Opioid Treatment Programs

Question 3 | Test | Table of Contents

U.S. Department of Health & Human Services

If you wish to increase the text size of this publication, maximize your window.
Click outside the box below, click Ctrl + several times, then scroll.
Questions? Email: [email protected]

- Giroir, B., Dowell, D., MD, MPH, Jones, C., PharmD, DrPH, Compton, W., MD, MPE, Kato, E., MD, MRP, Dubenitz, J., PhD, Ling, S., MD, Foster, D., DO, MS, MPH, Hertz, S., MD, Sokolowska, M., PhD, Steinberg, J., MD, MPH, Vythilingam, M., MD, and Clarke, T., PhD. (October 2019). HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics. U.S. Department of Health and Human Services, 1-6.

Peer-Reviewed Journal Article References:
Fishman, M., Wenzel, K., Vo, H., Wildberger, J., & Burgower, R. (2021). A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder. Addiction, 116(3), 548–557.

Hall, N. Y., Le, L., Majmudar, I., & Mihalopoulos, C. (2021). Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. Drug and Alcohol Dependence, 221, Article 108651.

Scott, K., Murphy, C. M., Yap, K., Moul, S., Hurley, L., & Becker, S. J. (2021). Health professional stigma as a barrier to contingency management implementation in opioid treatment programs. Translational Issues in Psychological Science, 7(2), 166–176.

What could the therapist say to a patient/client who expresses fears about opioid tapering? To select and enter your answer go to Test.

Section 4
Table of Contents